Newsroom | 194100 results

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the William Blair Growth Stock Conference in Chicago and the Jefferies Global Healthcare Conference in New York....

VANCOUVER, British Columbia--(BUSINESS WIRE)--WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) (“WELL” or the “Company”), a digital health company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, announced today that it has entered into an automatic share purchase plan (“ASPP“) with a broker in order to facilitate repurchases of the Company’s common shares (“Common Shares“) under its previously ann...

TORONTO--(BUSINESS WIRE)--Predictmedix AI Inc. (CSE: PMED) (OTC: PMEDF) (FRA: 3QP) (“Predictmedix” or the “Company”), a leader in AI-powered health and safety technology, is proud to announce a high-impact strategic alliance with Pacific Mechatronics Pvt. Ltd., a premier systems integrator with deep-rooted access to Asia-Pacific’s defence, aerospace, and national security ecosystems. This collaboration marks a major commercialization milestone—launching Predictmedix’s AI-driven Smart Health Sta...

ATLANTA--(BUSINESS WIRE)--Mirion Technologies, Inc. (“Mirion”) (NYSE: MIR), today announced its intent to offer $300.0 million aggregate principal amount of Convertible Senior Notes due 2030 (the “Notes”) in a private placement (the “Offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Mirion also intends to grant the initial purchasers of the Notes an option to purchase, within...

LAKE FOREST, Calif. & WOODLAND PARK, N.J.--(BUSINESS WIRE)--Summit Health Announces Internalization of Genomic Testing Cooperative State-of-The-Art Next Generation Sequencing DNA and RNA Profiling Tests...

PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in tissue-targeted AAV gene therapy, today announces the publication of a seminal research manuscript in Nature Communications: “Optimized AAV capsids for basal ganglia diseases show robust potency and distribution.” The study, led by Latus founder Beverly Davidson, Ph.D., details the discovery of a novel adeno-associated virus (AAV) capsid variant - AAV-DB-3 - that is poised to address the long-...

BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Kasra Kasraian, PhD, as Chief Technology Officer (CTO). Dr. Kasraian brings over 25 years of experience in product and process development, CMC strategy, and technical operations, spanning small and large molecules, as...

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced positive long-term durability data from the THRIVE phase 3 clinical trial of veligrotug (“veli”), an intravenously delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, in patients with active thyroid eye disease (TED). TED is an autoimmun...

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced that it has engaged Origin Merchant Partners as its financial and strategic advisor to advise on a range of opportunities aimed at maximizing shareholder value and expanding the reach of its innovative medical technologies. With the assistance of its financial and strategic advisor, the Company is exploring a range of...

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced it will present results from the Phase 3 SURPASS-ET clinical trial in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30-June 3 in Chic...